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1288Objective: The objective of this study was to assess early and late outcomes of pathologic N1 or N2 disease
unexpectedly detected in patients undergoing video-assisted thoracic surgery lobectomy for clinical stage I
non–small cell lung cancer.
Methods: We retrospectively reviewed the clinical and pathologic features of patients with unexpected N1 or N2
disease after video-assisted thoracic surgery lobectomy for clinical stage I disease and their early and late out-
comes, including survival and recurrence pattern.
Results: Between 2004 and 2008, 547 patients with clinical stage I disease underwent video-assisted thoracic
surgery lobectomy, and of these, 89 were found to have pathologic N1 (n ¼ 49) or N2 (n ¼ 40) disease. No
in-hospital mortality was noted during the postoperative period. For patients receiving adjuvant treatment, the
median time interval between discharge from surgical intervention and start of adjuvant treatment was
24 days. The median follow-up time was 21.3 months. The 3-year overall survival was 98% for patients with
N1 disease and 89% for patients with N2 disease. During follow-up, 33 (37%) patients had a recurrence. The
pattern of recurrence was locoregional in 7, distant in 21, and both in 5 patients. The 3-year disease-free survival
was 59% for patients with N1 disease and 33% for patients with N2 disease.
Conclusions: For patients with pathologic N1 or N2 disease after video-assisted thoracic surgery lobectomy,
survival was comparable with that after lobectomy through a thoracotomy. Even if lymph node metastasis is un-
expectedly detected during video-assisted thoracic surgery lobectomy for clinical stage I disease, there is no need
to convert to conventional thoracotomy. (J Thorac Cardiovasc Surg 2010;140:1288-93)Earn CME credits at
http://cme.ctsnetjournals.org
Over the last decade, video-assisted thoracic surgery
(VATS) lobectomies have been performed with increasing
frequency, and many thoracic surgeons have reported on
the technical feasibility and safety of the procedure.1-13
However, questions remain about whether VATS
lobectomy is oncologically effective or at least not inferior
to standard thoracotomy in patients with non–small cell
lung cancer (NSCLC). Therefore candidates for VATS
lobectomy are limited to patients with early-stage NSCLC,
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The Journal of Thoracic and Cardiovascular SurBecause false-negative results are intrinsic to preoperative
staging workups, unexpected N1 or N2 disease can be found
during or after VATS lobectomy. When lymph node metas-
tasis is detected by means of intraoperative frozen section bi-
opsy, it is difficult to decide whether VATS lobectomy
should be converted to open thoracotomy. Few studies
have investigated the outcomes of pathologic N1 or N2 dis-
ease that were unexpectedly detected in patients undergoing
VATS lobectomy for NSCLC.
To carefully select candidates for VATS lobectomy, we
have routinely performed integrated positron emission tomo-
graphic and computed tomographic (PET/CT) scans and, if
indicated, mediastinoscopy at our institution. Nonetheless,
we often encountered patients with unexpected N1 or N2 dis-
ease after VATS lobectomy. The objective of this study was
to assess early and late outcomes in patients who underwent
VATS lobectomy for clinical N0 disease but were found to
have pathologic N1 or N2 disease postoperatively.
MATERIALS AND METHODS
Between January 2004 and December 2008, 2107 consecutive patients
underwent curative-intent surgical intervention for NSCLC at our institu-
tion. Among these, 547 patients with clinical stage I disease underwent
VATS lobectomies. Of these, 89 patients were found to have pathologic
N1 (n ¼ 49) or N2 (n ¼ 40) disease. Their medical records were retrospec-
tively reviewed to assess clinical characteristics, early postoperativegery c December 2010
Abbreviations and Acronyms
DFS ¼ disease-free survival
NSCLC ¼ non–small cell lung cancer
OS ¼ overall survival
PET/CT ¼ positron emission tomographic and
computed tomographic
VATS ¼ video-assisted thoracic surgery
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approved by the Institutional Review Board of Samsung Medical Center.
The routine preoperative workup included pulmonary function tests, CT
scans of the chest and upper abdomen, PET/CT scans, flexible bronchos-
copy, and brain magnetic resonance imaging. For patients with preopera-
tively proved NSCLC, cervical mediastinoscopy was routinely performed
regardless of the findings of CT or PET/CT scans. Candidates for VATS
lobectomy were patients with clinical stage I disease, peripherally located
lesions (no endobronchial lesions), and a tumor of 6 cm in diameter or
smaller. Patients were required to be able to tolerate single-lung ventilation,
as determined by preoperative pulmonary function tests.
VATS lobectomy was performed after achievement of single-lung anes-
thesia by using 2 ports and a utility incision without rib spreading. A 15-mm
trocar for the 10-mm 30 thoracoscope was placed through the seventh or
eighth intercostal space in the posterior axillary line. A 4-cm utility incision
was made through the fourth or fifth intercostal space in the anterior axillary
line. An additional 5-mm trocar was placed through the sixth or seventh in-
tercostal space in the posterior scapular line. The vessels and bronchi of the
target lobe were individually dissected. Systematic lymph node dissection
was mandatory. We avoided touching the lymph node itself and avoided
rupturing the capsule of the lymph node. Mediastinal lymph node dissection
consisted of en bloc resections of all nodes at stations 2R, 4R, 7, 8, 9, and
10R for right-sided tumors and nodes at stations 4L, 5, 6, 7, 8, 9, and 10L
for left-sided tumors. When lymph node enlargement was observed or
lymph node metastasis was suspected, frozen section biopsies were
performed during surgical intervention. All specimens were placed in an
impermeable bag and removed through the utility incision.
Adjuvant chemotherapy, radiotherapy, or concurrent chemoradiation
was administered to patients who were able to tolerate additional treatments.
Patients were regularly evaluated by means of CT scanning every 3 to 4
months for the first 2 years after surgical intervention and then every
6 months thereafter. Patients were annually evaluated with PET/CT scans.
Locoregional recurrence was defined as that occurring within the ipsilateral
hemithorax, including the pleura and mediastinal lymph nodes. Distant re-
currence was defined as that developing within the contralateral hemithorax
or a distant solid organ. When recurrence was suspected, we tried to obtain
histologic or unequivocal radiologic proof. In cases lost to follow-up,
a telephone interview was conducted to determine late outcomes.
Descriptive statistics were used to assess patients’ demographic character-
istics and outcomes. Normally distributed continuous data were expressed as
means  standard deviations. Categorical data were expressed as counts and
proportions. Student t tests and the c2 test or Fisher exact test were used to
compare continuous and categorical variables, respectively. Overall survival
(OS) was defined as the time from the date of surgical intervention until the
last date of follow-up for patients who remained alive or until death. Disease-
free survival (DFS) was defined as the time from the date of surgical inter-
vention to recurrence or death. Survival curves were prepared by using the
Kaplan–Meier method and were compared univariately with the log-rank
test. A multivariate logistic regression model evaluating age, sex, tumor
size, pathologic characteristics, and dissected number of lymph nodes was
performed to determine which factors were associated with unexpected N1The Journal of Thoracic and Caror N2 disease; nonsignificant variables were excluded in a stepwise fashion
to obtain the final model. A multivariate analysis with Cox proportional haz-
ards model was performed to determine which factors were significantly as-
sociated with survival. All statistical tests were 2-sided and performed with
Stata software version 10.0 (StataCorp, College Station, Tex).RESULTS
Clinical and Pathologic Features
The study included 46 men and 43 women (Table 1) with
a mean age of 57 years (range, 35–75 years), and 10 (11%)
patients aged 70 years or older. All patients had an Eastern
Cooperative Oncology Group performance status of
0 (n ¼ 67) or 1 (n ¼ 22). Thirty-four (38%) patients had
a history of comorbidity, including malignancy in 8, coro-
nary artery disease in 3, and diffuse interstitial lung disease
in 2. The most common histologic type was adenocarcinoma
(84 [94%] patients). All patients received PET/CT scans,
and 46 (52%) underwent mediastinoscopy; preoperative
staging workup revealed that all patients had clinical stage
I disease. During surgical intervention, lymph node metasta-
ses were confirmed by means of frozen section biopsy in
17 (19%) patients, but none of these patients underwent
conversion to open thoracotomy. The extent of pulmonary
resection was lobectomy in 82 (92%) patients and bilobec-
tomy in 7 (8%) patients. Except for 1 case of microscopic
residual tumor at the bronchial resection margin, there
were no cases of incomplete resection.
Pathologic N1 or N2 disease was found postoperatively in
49 and 40 patients, respectively. Pathologic T stage, tumor
differentiation, and number of dissected lymph nodes were
significant predictors of unexpected pathologic N1 or N2 dis-
ease (Table 2). The median numbers of metastatic and dis-
sected lymph nodes were 2 (range, 1–14) and 23 (range,
10–56), respectively. Among patients with pathologic N2 dis-
ease, 30 (75%) had single-station involvement, and 14 (35%)
had extracapsular invasion. The median diameter of the larg-
est metastatic lymph nodes was 5 mm (range, 0.01–21 mm).
Details on pathologic N2 disease are summarized in Table 3.
Early Postoperative Outcomes
No in-hospital mortality was noted during the postopera-
tive period. Twenty-two complications occurred in 16
(18%) patients. The most common complication was pro-
longed air leak (8 patients). There were 3 episodes of acute
lung injury, 2 episodes of atrial fibrillation, 2 episodes of
pneumonia, 2 episodes of chylothorax, and 1 episode of
postoperative bleeding. The median duration of chest tube
placement was 4 days (range, 1–25 days). The median length
of hospital stay was 6 days (range, 2–35 days). Postopera-
tively, 77 (87%) patients underwent adjuvant chemotherapy
(n ¼ 46), radiotherapy (n ¼ 7), or concurrent chemoradia-
tion (n¼ 24). The remaining 12 patients did not undergo ad-
juvant treatment because of comorbidity (n ¼ 5), old age or
poor performance status (n¼ 3), and patient refusal (n¼ 4).
The median time interval between the discharge fromdiovascular Surgery c Volume 140, Number 6 1289
TABLE 1. Baseline clinical and pathologic characteristics (n ¼ 89)
All patients (n ¼ 89) Patients with pN1 disease (n ¼ 49) Patients with pN2 disease (n ¼ 40)
Characteristic No. % No. % No. % P value
Age, y (mean) 57.3 (35–75) 56.7 (40–72) 58.1 (35–75) .45
Sex .046
Male 46 52 30 61 16 40
Female 43 48 19 39 24 60
ECOG performance .15
0 67 75 34 69 33 83
1 22 25 15 31 7 17
Comorbidity .23
Yes* 34 38 16 33 18 45
No 55 62 33 67 22 55
Histology .31
ADC 84 42 45 92 39 98
SCC 3 48 3 6 0 0
Othersy 2 6 1 2 1 2
BAC component .35
Yes 22 25 14 29 8 20
No 67 75 35 71 32 80
Tumor size, mm (mean) 3.0 (0.8–8.5) 3.0 (1.4–8.0) 3.1 (0.8–8.5) .46
SUVmax of primary tumor (mean) 8.4 (2.2–21.9) 8.6 (2.2–18.7) 8.1 (2.6–21.9) .78
Tumor differentiation .2
WD 6 7 5 10 1 2
MD 68 76 34 69 34 85
PD 15 17 10 21 5 13
Pathologic T stage .55
T1 25 28 15 31 10 25
T2 60 68 33 67 27 68
T3 2 2 1 2 1 2
T4 2 2 0 0 2 5
pN1, Pathologic N1; pN2, pathologic N2; ECOG, Eastern Cooperative Oncology Group; ADC, adenocarcinoma; SCC, squamous cell carcinoma; BAC, bronchioloalveolar carci-
noma; SUVmax, maximum standardized uptake value; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated. *Comorbidities included hypertension in
23 patients, diabetes mellitus in 9 patients, malignancy in 8 patients, coronary artery disease in 3 patients, diffuse interstitial lung disease in 2 patients, and chronic renal disease in 1
patient. y‘‘Others’’ includes sarcomatoid carcinoma in 1 patient and basaloid carcinoma in 1 patient.
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24 days (range, 14–65 days). Of the 70 patients who re-
ceived chemotherapy, 51 (73%) received their full planned
dose on schedule, and 6 (9%) were administered the full
course of planned doses of chemotherapy with a delay in 1TABLE 2. Logistic regression: Predictors of unexpected pathologic N1
or N2 disease (n ¼ 547)
Factor OR 95% CI P value
Pathologic T stage .003
T1 (n ¼ 274) 1
T2 (n ¼ 252) 2.66 1.55–4.58 .000
T3 (n ¼ 11) 4.23 0.99–18.04 .051
T4 (n ¼ 10) 2.36 0.56–9.94 .243
Tumor differentiation .000
WD (n ¼ 214) 1
MD (n ¼ 240) 9.95 4.35–22.8 .000
PD (n ¼ 55) 15.6 5.63–43.2 .000
Unknown (n ¼ 38) 6.02 1.68–21.6 .006
No. of dissected LNs 1.03 1.0–1.06 .05
OR, Odds ratio; CI, confidence interval; WD, well differentiated; MD, moderately dif-
ferentiated; PD, poorly differentiated; LN, lymph node.
1290 The Journal of Thoracic and Cardiovascular Suror more cycles. Fifty-seven (81%) patients received all in-
tended cycles with or without delay. Reasons for dose delay
or dose reduction were neutropenia (n ¼ 15), azotemia
(n ¼ 2), and gastrointestinal symptoms (n ¼ 2).Survival and Recurrence Pattern
Follow-up was complete for all patients (Figure 1). The me-
dian follow-up time was 21.3 months. At the end of follow-up,
there were 85 (96%) surviving patients. Median OS time was
not reached. For patients with N1 disease, OS was 98% at 1
year and 98% at 3 years. For patients with N2 disease, OS
was 98% at 1 year and 89% at 3 years. During follow-up,
33 (37%) patients had a recurrence. The pattern of recurrence
was locoregional in 7, distant in 21, and both in 5 patients
(Table 4). Median DFS time was 52 months (95% confidence
interval, 46–58 months) for patients with pathologic N1
disease and 30 months (95% confidence interval, 24–35
months) for those with pathologic N2 disease. For patients
with N1 disease, DFS was 86% at 1 year and 59% at 3 years.
For patients with N2 disease, DFS was 75% at 1 year andgery c December 2010
TABLE 3. Pathologic features of 40 patients with N2 disease after
VATS lobectomy
No. %
No. of positive LN stations
Single 30 75
Multiple 10 25
Extracapsular invasion
Yes 14 35
No 26 65
Skip metastasis*
Yes 20 50
No 20 50
Diameter of the largest metastatic LN, mm (median) 6 (0.1–21)
5 mm 15 38
5-10 mm 17 42
>10 mm 8 20
LN, Lymph node. *Skip metastasis indicates mediastinal lymph node metastasis with-
out peribronchial or hilar lymph node metastasis.
FIGURE 1. Overall survival (A) and disease-free survival (B) after VATS
lobectomy in patients with pathologic N1 and N2 disease.
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performed to determine which factors were significantly asso-
ciated with DFS (Table 5). Adjuvant treatment was the only
independent predictive factor associated with increased DFS.
DISCUSSION
Although the feasibility and safety of VATS lobectomy have
been demonstrated by many reports, it remains controversial in
terms of oncologic efficacy compared with open thoracotomy
in patients with NSCLC.1-13 Concerns over the oncologic
reliability of VATS lobectomy arise from the possibility
of insufficient lymph node dissection.13-15 When lymph node
metastasis is unexpectedly detected during VATS lobectomy,
it is difficult to decide whether to convert VATS to
open thoracotomy. We therefore focused on patients with
unexpected N1 and N2 disease after VATS lobectomy.
A retrospective review of clinical and pathologic features,
perioperative results, recurrence patterns, and survival
outcomes was performed. We found that early postoperative
outcomes were excellent and that survival was also favorable.
Our results are in agreement with those of previous stud-
ies that demonstrated favorable outcomes when lymph node
metastasis was incidentally detected during primary surgical
intervention for clinical N0 disease.16-18 Inoue and
colleagues16 reported a 5-year survival of 28% of 219 pa-
tients with N2 disease undergoing complete resection. Cer-
folio and Bryant17 also reported a 5-year survival of 35%
of 148 patients who underwent complete resection for un-
suspected N2 disease. However, these reports were based
on cases in which surgical resection was performed by
means of thoracotomy. Few reports examined the outcomes
of pathologic N1 and N2 disease after VATS lobectomy. Re-
cently, Watanabe and associates19 reported a 5-year DFS of
60.9% for 37 patients with clinical N0 and pathologic N2
disease who underwent VATS lobectomy. In our series the
3-year OS and DFS rates for patients with N2 diseaseThe Journal of Thoracic and Carwere 89% and 33%, respectively. These survival rates are
favorable considering the presence of pathologic N2 disease.
Our favorable outcomes can be explained by the fact that
VATS lobectomy was performed in highly selected patients.
We routinely performed PET/CT scans and cervical media-
stinoscopy for accurate staging. VATS lobectomy was
planned only when patients had clinical stage I disease based
on such meticulous preoperative workups. This suggests that
even if pathologic N1 or N2 disease is unexpectedly detected
at surgical intervention, the extent of nodal metastasis is
likely to be minimal and microscopic. This explanation is
supported by our findings that N2 disease mostly involved
single stations and that the median diameter of the largest
metastatic lymph nodes was only 5 mm. In addition, al-
though patients with N1 disease had better survival times
than those with N2 disease, there was no statistically signif-
icant difference in OS and DFS. This suggests that patients
with N2 disease in our study population were in relatively
earlier stages of disease than those with bulky N2 disease
in other series. As a result, in patients who were preopera-
tively staged as having N0 disease but turned out to have
pathologic N2 disease after VATS lobectomy, survival ratesdiovascular Surgery c Volume 140, Number 6 1291
TABLE 4. Incidence and pattern of recurrence after VATS lobectomy in patients with pathologic N1 and N2 disease
All patients (n ¼ 89) Patients with pN1 disease (n ¼ 49) Patients with pN2 disease (n ¼ 40)
No. % No. % No. %
Incidence 33 37 15 31 18 45
Disease-free interval, mo (median) 12.7 14 12.1
Pattern of recurrence
Loco-regional 7 8 4 8 3 8
Distant 21 24 8 16 13 33
LþD 5 6 3 6 2 5
pN1, Pathologic N1; pN2, pathologic N2; LþD, locoregional plus distant.
TABLE 5. Univariate and multivariate associations between clinicopathologic factors and disease-free survival
Univariate analysis Multivariate analysis
Factor HR 95% CI P value HR 95% CI P value
Pathologic N stage .21 .54
N1 (n ¼ 49) 1 1
N2 (n ¼ 40) 1.53 0.79–2.99 1.31 0.55–3.13 .9
BAC component .68 .83
No (n ¼ 67) 1 1
Yes (n ¼ 22) 0.85 0.38–1.87 1.11 0.44–2.84
Extracapsular invasion .79 .62
No (n ¼ 63) 1 1
Yes (n ¼ 26) 1.11 0.51–2.44 1.26 0.51–3.13
Diameter of the largest metastatic LN .43 .6
10 mm (n ¼ 75) 1 1
>10 mm (n ¼ 14) 1.44 0.59–3.53 0.76 0.26–2.16
Adjuvant therapy .000 .02
Not done (n ¼ 12) 1 1
Done (n ¼ 77) 0.24 0.11–0.54 0.21 0.06–0.81
HR, Hazard ratio; CI, confidence interval; BAC, bronchioloalveolar carcinoma; LN, lymph node.
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tomy through a thoracotomy from previous reports.
Several studies have found favorable outcomes of primary
surgical intervention for minimal N2 disease.20-22 Andre and
coworkers20 reported a 5-year survival of 34% for 244 pa-
tients with single-level minimal N2 disease who underwent
primary surgical intervention. Ichinose and colleagues21 re-
ported a 5-year survival of 43% for 209 patients who had
not received neoadjuvant therapy and were found to have
single-level N2 disease. Favorable outcomes of patients with
minimal N2 disease can be attributed to their relatively early
stage of disease compared with bulky, clinical N2 disease.
The probability of distant micrometastases in patients with
minimal N2 disease is likely to be lower than in those with
clinical N2 disease. Because the possibility of extracapsular
invasion is also low in patients with minimal N2 disease, en
bloc lymphadenectomy can be easily done, even when using
the VATS approach. This is in line with our findings that the
pattern of recurrence occurred mostly through distant metasta-
sis and that the incidence of locoregional recurrence was low.
It is unknown whether lymph node dissection can be
performed as effectively in VATS as in open thoracotomy.
Scientifically measuring and comparing the performance of1292 The Journal of Thoracic and Cardiovascular Sursurgical techniques is essentially difficult. Nonetheless, in-
trinsic limitations of exposure and manipulation of the
VATS approach can be overcome by the highly magnified
view from video assistance and advances in endoscopic in-
struments. As experiences in VATS lobectomy accumulate,
the completeness of lymph node dissection might improve.
Sagawa and associates14 performed VATS lobectomy and
lymph node dissection followed by immediate thoracotomy
to look for ‘‘remnant’’ lymph nodes in their prospective trial.
They found that the remnant lymph nodes missed by VATS
were only 2% to 3%. Scott and coworkers13 showed that the
median total number of lymph nodes retrieved was similar
for both VATS lobectomy (15 nodes) and open lobectomy
(19 nodes). In our series the median number of dissected
lymph nodes was 23, which was not inferior to that of the
conventional open approach. Considering the microscopic
nature of lymph node metastasis and the low incidence of lo-
coregional recurrence, it does not seem that opening the
chest would have resulted in more favorable long-term out-
comes in this subgroup of patients with minimal N2 disease.
The late outcomes might also have been improved by the
effect of adjuvant therapy. This can be inferred from our
findings that adjuvant therapy was the only independentgery c December 2010
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87% of the patients received adjuvant therapy, and all of
these patients completed the schedule without serious toxic-
ities. In addition, adjuvant therapy was initiated within a me-
dian time interval of 24 days after discharge from surgical
intervention. If we had converted VATS to open thoracot-
omy for more complete lymph node dissection, the start of
adjuvant therapy might have been delayed by a longer period
of wound healing and lower postoperative performance sta-
tus. Earlier initiation of adjuvant therapy and its good com-
pliance rate can be attributed to the VATS approach.
Because this is a retrospective noncomparative study, our
findings should be interpreted with caution. We performed
VATS lobectomy in selected patients with favorable prog-
nostic characteristics. This might have predisposed the study
sample to favorable outcomes compared with those seen in
patients undergoing open surgical intervention. Further-
more, patients who were converted to open surgical inter-
vention during VATS lobectomy were not included in this
study. Although multivariate analyses showed that adjuvant
therapy was the only independent predictor for DFS, adju-
vant therapy was selectively performed in patients with
good postoperative performance status. For these reasons,
this study is subject to selection bias. Prospective random-
ized trials are required for more conclusive results. Also,
the follow-up duration was relatively short, making it diffi-
cult to conclude whether recurrence-free survival rates
were truly favorable for patients with N1 or N2 disease. Be-
cause we did not measure the thoroughness of lymph node
dissection, we cannot simply assume that lymph node dis-
section was done in VATS as thoroughly as in open thora-
cotomy just because the number of dissected lymph nodes
was not inferior to that of the conventional open approach.
Further studies are needed to confirm the current results.
In summary, we retrospectively reviewed the clinical and
pathologic features of patients with unexpected N1 or N2
disease after VATS lobectomy and their early and late out-
comes. We found that early postoperative outcomes were
excellent without any in-hospital mortality and that late sur-
vival outcomes were also favorable, despite the presence of
lymph node metastasis. This might be due to the fact that
VATS lobectomy was performed in patients with clinical
N0 disease, and lymph node metastasis was possibly mini-
mal and microscopic. Based on our findings, we suggest
that for patients staged as having N0 disease through metic-
ulous preoperative workup, there is no need to convert to
conventional thoracotomy even if the intraoperative frozen
section biopsy results of the lymph nodes are positive for
malignancy during VATS lobectomy.
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